Dermalyte is an early-stage medical device venture developing a clinically oriented transdermal delivery platform designed to functionally replace traditional intravenous (IV) infusion for the administration of essential minerals and electrolytes. The company addresses a fundamental limitation in current healthcare workflows, where IV infusion remains the default standard despite its invasiveness, delays in therapy initiation, and reliance on trained venous access.

Dermalyte’s innovation focuses on system-level delivery architecture that enables controlled, clinically relevant systemic administration without the need for venous cannulation. Unlike conventional transdermal patches intended for slow or localized delivery, the platform is designed to meet the performance requirements of acute care environments, including hospitals, emergency departments, and other time-sensitive clinical settings.

While microneedle-based interfaces represent one possible technological embodiment, the core invention is not limited to a specific material or fabrication method. Instead, it lies in the delivery control principles and functional equivalence framework that enable reproducible systemic outcomes comparable to IV therapy for selected indications. This approach allows for scalability and future expansion beyond minerals and electrolytes to additional therapeutic categories.

Dermalyte is currently in the pre–proof-of-concept stage, advancing intellectual property protection, feasibility validation, and early experimental planning. The company is actively seeking strategic collaborations with academic research groups, clinical partners, regulatory advisors, and funding programs to support early validation and prepare for subsequent clinical and commercial development.